Short-Term Treatment with Empagliflozin Resulted in Dehydration and Cardiac Arrest in an Elderly Patient with Specific Complications: A Case Report and Literature Review

Sopak Supakul; Yurika Nishikawa; Masanori Teramura; Tetsuro Takase

doi:10.3390/medicina58060815

Short-Term Treatment with Empagliflozin Resulted in Dehydration and Cardiac Arrest in an Elderly Patient with Specific Complications: A Case Report and Literature Review

Sopak Supakul
, Yurika Nishikawa
, Masanori Teramura
, Tetsuro Takase

Research output: Contribution to journal › Article › peer-review

3 Citations (Scopus)

Abstract

Empagliflozin is a sodium-glucose cotransporter-2 inhibitor widely used in the treatment of diabetes mellitus and heart failure. Our case study involved a 68-year-old patient who was admitted to the hospital because of a cerebral infarction. The patient was simultaneously diagnosed with diabetes mellitus and heart failure, for which empagliflozin was initiated. However, food and fluid intake were reduced due to poor appetite. In addition to the side effects of empagliflozin, the patient developed severe dehydration and cardiac arrest. Careful assessment of dehydration and preventive water intake is recommended in elderly patients and those with neurological deficits, especially when receiving empagliflozin.

Original language	English
Article number	815
Journal	Medicina (Lithuania)
Volume	58
Issue number	6
DOIs	https://doi.org/10.3390/medicina58060815
Publication status	Published - 06-2022
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

All Science Journal Classification (ASJC) codes

General Medicine

Access to Document

10.3390/medicina58060815

Cite this

@article{4c35ebadabe84a708b08827670771fd4,

title = "Short-Term Treatment with Empagliflozin Resulted in Dehydration and Cardiac Arrest in an Elderly Patient with Specific Complications: A Case Report and Literature Review",

abstract = "Empagliflozin is a sodium-glucose cotransporter-2 inhibitor widely used in the treatment of diabetes mellitus and heart failure. Our case study involved a 68-year-old patient who was admitted to the hospital because of a cerebral infarction. The patient was simultaneously diagnosed with diabetes mellitus and heart failure, for which empagliflozin was initiated. However, food and fluid intake were reduced due to poor appetite. In addition to the side effects of empagliflozin, the patient developed severe dehydration and cardiac arrest. Careful assessment of dehydration and preventive water intake is recommended in elderly patients and those with neurological deficits, especially when receiving empagliflozin.",

keywords = "dehydration, empagliflozin, sodium-glucose cotransporter-2 (SGLT-2) inhibitor",

author = "Sopak Supakul and Yurika Nishikawa and Masanori Teramura and Tetsuro Takase",

note = "Publisher Copyright: {\textcopyright} 2022 by the authors. Licensee MDPI, Basel, Switzerland.",

year = "2022",

month = jun,

doi = "10.3390/medicina58060815",

language = "English",

volume = "58",

journal = "Medicina (Lithuania)",

issn = "1010-660X",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "6",

}

TY - JOUR

T1 - Short-Term Treatment with Empagliflozin Resulted in Dehydration and Cardiac Arrest in an Elderly Patient with Specific Complications

T2 - A Case Report and Literature Review

AU - Supakul, Sopak

AU - Nishikawa, Yurika

AU - Teramura, Masanori

AU - Takase, Tetsuro

PY - 2022/6

Y1 - 2022/6

N2 - Empagliflozin is a sodium-glucose cotransporter-2 inhibitor widely used in the treatment of diabetes mellitus and heart failure. Our case study involved a 68-year-old patient who was admitted to the hospital because of a cerebral infarction. The patient was simultaneously diagnosed with diabetes mellitus and heart failure, for which empagliflozin was initiated. However, food and fluid intake were reduced due to poor appetite. In addition to the side effects of empagliflozin, the patient developed severe dehydration and cardiac arrest. Careful assessment of dehydration and preventive water intake is recommended in elderly patients and those with neurological deficits, especially when receiving empagliflozin.

AB - Empagliflozin is a sodium-glucose cotransporter-2 inhibitor widely used in the treatment of diabetes mellitus and heart failure. Our case study involved a 68-year-old patient who was admitted to the hospital because of a cerebral infarction. The patient was simultaneously diagnosed with diabetes mellitus and heart failure, for which empagliflozin was initiated. However, food and fluid intake were reduced due to poor appetite. In addition to the side effects of empagliflozin, the patient developed severe dehydration and cardiac arrest. Careful assessment of dehydration and preventive water intake is recommended in elderly patients and those with neurological deficits, especially when receiving empagliflozin.

KW - dehydration

KW - empagliflozin

KW - sodium-glucose cotransporter-2 (SGLT-2) inhibitor

UR - https://www.scopus.com/pages/publications/85132591839

UR - https://www.scopus.com/pages/publications/85132591839#tab=citedBy

U2 - 10.3390/medicina58060815

DO - 10.3390/medicina58060815

M3 - Article

C2 - 35744078

AN - SCOPUS:85132591839

SN - 1010-660X

VL - 58

JO - Medicina (Lithuania)

JF - Medicina (Lithuania)

IS - 6

M1 - 815

ER -

Short-Term Treatment with Empagliflozin Resulted in Dehydration and Cardiac Arrest in an Elderly Patient with Specific Complications: A Case Report and Literature Review

Abstract

UN SDGs

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this